Business briefs: Lundbeck and Otsuka; Omnicom; Vivus

Share this article:

Otsuka is partnering with Lundbeck on an Alzheimer's drug, LU AE58054, a selective 5-HT6 receptor antagonist entering Phase III clinical trials. Otsuka agreed to pay $150 million upfront and  $675 million in benchmarked payments if the drug progresses. It's an evolution of an alliance on CNS drugs, including Abilify, that the companies formed in 2011.

Omnicom said Tom Harrison, longtime head of its Diversified Agencies Services unit which houses the holding company's healthcare agencies, will become chairman emeritus of the division April 1. Harrison, whose namesake agency Harrison & Star was acquired by Omnicom in 1992, has headed DAS, as it is known, for 16 years. Dale Adams succeeded Harrison as CEO in 2011, and Harrison continued as chairman of the group.

The Street's Adam Feuerstein is not a fan of how weight-loss drug maker Vivus has framed its most recent financial strategy—a $110 million “non equity financing” deal with Pharmakon Advisors—as something other than debt. According to the deal Vivus announced Tuesday, Pharmakon is providing it with a tranche that will be divided into an initial payment of $50 million, and the balance being chipped away at in increments as needed, in exchange for quarterly repayments that will kick in during next year's second quarter. Payments will be pegged to Qsymia sales. Among the problems Feurstein has with the deal include that Vivus will end up paying almost $70 million for that first $50 million, putting the interest rate at around 13%. Further, he wrote that the company's Qsymia patent and trademarks are among the loan's collateral and “if Vivus defaults, Pharmakon gets basically everything of value.” Although Qsymia is the first new prescription weight-loss drug to hit the market in decades, the California company has been struggling with low sales which have been partially attributed to costs: according to Bloomberg, patients could end up paying around $200 a month for the medication, which is taken like a chronic medication, instead of a short-term therapy. Recent attempts to boost sales have included a free trial offer, a weight-loss app marketed to healthcare providers and an attempt to go beyond mail-order to retail-level distribution. The FDA is expected to decide on the retail option in April.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.